← Leaderboards
Alana L Welm
Glycomira, Llc
$9,642,442
Attributed
$10,408,369
Total exposure
18
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,634,909 · 19
By mechanism
U54$16,779,358 · 12
R01$3,714,856 · 2
R21$750,187 · 2
R43$210,000 · 1
P30$180,508 · 2
Top collaborators
- Michael T Lewis18 shared
- Bryan E. Welm12 shared
- Gabor T Marth3 shared
- Adam L Cohen2 shared
- Christos Vaklavas2 shared
- Thomas Preston Kennedy1 shared
- Glenn D Prestwich1 shared
- Justin Rodney Savage1 shared
Most similar at Glycomira, Llc
Same institution · by research overlap
- Thomas Preston Kennedy$609,145
- Justin Rodney Savage$2,775,433
- Narayanam Venkateswara Rao$124,938
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsResponseMalignant Breast NeoplasmClinical TrialsBreast Cancer TherapyCollaborationsFundingBasePre-ClinicalCollegeProgramsMemberSitePharmacotherapyMammary NeoplasmsCellsXenograft ModelInstitutesResistancePilot ProjectsCollectionIn VivoResearch Personnel
Grant awards (78)
PDX Trial Center for Breast Cancer Therapy$1,144,535
U54 · FY2025 · CA · contact PI
Research Project 2: Identify and validate efficacious therapies for metastatic breast cancer$295,107
U54 · FY2025 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$145,941
U54 · FY2025 · CA · contact PI
Administrative Core$62,286
U54 · FY2025 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$996,258
U54 · FY2024 · CA · contact PI
Research Project 2: Identify and validate efficacious therapies for metastatic breast cancer$301,767
U54 · FY2024 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$139,770
U54 · FY2024 · CA · contact PI
Administrative Core$73,833
U54 · FY2024 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$1,187,139
U54 · FY2023 · CA · contact PI
A feasibility trial of functional precision cancer medicine to inform treatment selection in metastatic breast cancer$211,494
R21 · FY2023 · CA
Administrative Core$197,857
U54 · FY2023 · CA · contact PI
Research Project 2: Identify and validate efficacious therapies for metastatic breast cancer$197,856
U54 · FY2023 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$197,856
U54 · FY2023 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$520,759
U54 · FY2022 · CA · contact PI
Role of RON kinase in anti-tumor immune responses$341,867
R01 · FY2022 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$296,777
U54 · FY2022 · CA · contact PI
Core-001$200,000
U54 · FY2022 · CA · contact PI
Core-001$200,000
U54 · FY2022 · CA · contact PI
Tolinapant efficacy in a subset of triple negative breast cancers$200,000
U54 · FY2022 · CA · contact PI
Targeting mitochondrial dependencies in chemo resistant triple negative breast cancer$200,000
U54 · FY2022 · CA · contact PI
A feasibility trial of functional precision cancer medicine to inform treatment selection in metastatic breast cancer$179,403
R21 · FY2022 · CA
PDX Trial Center for Breast Cancer Therapy$1,240,619
U54 · FY2021 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$449,396
U54 · FY2021 · CA · contact PI
Role of RON kinase in anti-tumor immune responses$348,844
R01 · FY2021 · CA · contact PI
Multi-omic, Exposure-informed, Genealogical Approach (mErGE)$119,886
U54 · FY2021 · CA · contact PI
Administrative Core$84,863
U54 · FY2021 · CA · contact PI
PDX Core$34,227
U54 · FY2021 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$1,240,654
U54 · FY2020 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$449,406
U54 · FY2020 · CA · contact PI
Role of RON kinase in anti-tumor immune responses$348,844
R01 · FY2020 · CA · contact PI
Administrative Core$120,000
U54 · FY2020 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$120,000
U54 · FY2020 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$119,960
U54 · FY2020 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$119,960
U54 · FY2020 · CA · contact PI
Administrative Core$84,866
U54 · FY2020 · CA · contact PI
Cell Response and Regulation (CRR)$66,235
P30 · FY2020 · CA · contact PI
PDX Core$34,227
U54 · FY2020 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$1,240,654
U54 · FY2019 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$462,687
U54 · FY2019 · CA · contact PI
Role of RON kinase in anti-tumor immune responses$338,378
R01 · FY2019 · CA · contact PI
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Metastatic Breast Cancer$160,604
R21 · FY2019 · CA · contact PI
Administrative Core$85,200
U54 · FY2019 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$62,293
U54 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$51,416
P30 · FY2019 · CA · contact PI
PDX Core$34,047
U54 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$14,284
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$11,113
P30 · FY2019 · CA · contact PI
PDX Core$10,383
U54 · FY2019 · CA · contact PI
Administrative Core$10,383
U54 · FY2019 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$10,381
U54 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$8,214
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$8,169
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$5,972
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$4,268
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$3,813
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$3,571
P30 · FY2019 · CA · contact PI
Cell Response and Regulation Program (Project-002)$3,453
P30 · FY2019 · CA · contact PI
Role of RON kinase in anti-tumor immune responses$348,844
R01 · FY2018 · CA · contact PI
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Metastatic Breast Cancer$198,686
R21 · FY2018 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$176,157
U54 · FY2018 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$175,435
U54 · FY2018 · CA · contact PI
Administrative Core$29,361
U54 · FY2018 · CA · contact PI
PDX Core$29,360
U54 · FY2018 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$29,359
U54 · FY2018 · CA · contact PI
Administrative Core$29,240
U54 · FY2018 · CA · contact PI
PDX Core$29,240
U54 · FY2018 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$29,239
U54 · FY2018 · CA · contact PI
PDX Trial Center for Breast Cancer Therapy$2,482,191
U54 · FY2017 · CA · contact PI
Research Project 1: Identification and validation of efficacious therapies for breast cancer using patient-derived specimens$825,486
U54 · FY2017 · CA · contact PI
Short-form Ron Kinase in Tumor Progression and Metastasis$381,617
R01 · FY2017 · CA · contact PI
Administrative Core$184,412
U54 · FY2017 · CA · contact PI
PDX Core$68,045
U54 · FY2017 · CA · contact PI
Short-form Ron Kinase in Tumor Progression and Metastasis$283,678
R01 · FY2015 · CA · contact PI
Short-form Ron Kinase in Tumor Progression and Metastasis$160,449
R01 · FY2015 · CA · contact PI
Short-form Ron Kinase in Tumor Progression and Metastasis$429,549
R01 · FY2014 · CA · contact PI
Short-form Ron Kinase in Tumor Progression and Metastasis$366,674
R01 · FY2013 · CA · contact PI
Short-form Ron Kinase in Tumor Progression and Metastasis$366,112
R01 · FY2012 · CA · contact PI
Novel Glycosaminoglycan Ethers for Prevention of Metastasis$210,000
R43 · FY2011 · CA